Markets

Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies

Aug 17, 2026 · 08:56 AM ET· updated 1h ago

The Patent Claims are for the Intended Commercial Formulation of ART27.13Expected to Extend Patent Protection for ART27.13 through 2041SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences,

Why It Matters

Artelo got official approval to protect how it makes and sells a new medicine it's testing. This means the company can keep others from copying this medicine's recipe until 2041, which gives it more time to make money from it.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ARTL0.78

-0.01 (-1.54%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.